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Abstract The polymorphism of p53 codon 72, a transversion
of G to C (Arg to Pro), has been demonstrated to be associated
with the risk for lung cancer. However, individual studies
conducted in Asians have provided conflicting and inconclu-
sive findings. Thus, we performed a meta-analysis by pooling
all currently available case–control studies to estimate the
effect of p53 codon 72 Arg/Pro polymorphism on the devel-
opment of lung cancer. The pooled odds ratios (ORs) with the
corresponding 95 % confidence intervals (95 %CIs) were
calculated to assess this effect. A total of 14 individual studies
involving 7,929 cases and 5,924 controls were included into
this meta-analysis according to the inclusion criteria. The
overall OR for the dominant genetic model indicated that the
p53 codon 72 Arg/Pro variant was positively correlated with
lung cancer risk (ORArg/Pro + Pro/Pro vs. Arg/Arg=1.14, 95 %CI
1.07–1.23, POR<0.001). Similar results were found in the
stratified analysis of population-based studies. The histologi-
cal types of lung cancer and smoking status seemed to exert no
effect on the lung cancer risk. Sensitivity analysis confirmed
the stability of the above findings. The updated meta-analysis
suggests that the p53 codon 72 Arg/Pro polymorphism is a
risk factor for lung cancer in the Asian population. However,
the potential role of gene–environment interaction in lung
cancer susceptibility needs further investigation in future stud-
ies with high quality.
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Introduction
Lung cancer is one of the leading causes of cancer-related
death in the world and a major public health challenge
during the past few decades [1]. Tobacco smoking and
alcohol consumption have been well-established as risk
factors for lung cancer [2]. Despite the obvious carcinogenic
effects of smoking and alcohol consumption, not all ex-
posed individuals develop lung cancer, suggesting that some
other factors including genetic polymorphism may also con-
tribute to the pathogenesis of lung cancer. A number of
genetic polymorphisms have been demonstrated to alter
the risk of this deadly disease independently or in combina-
tion with each other as well as the environmental exposures
[2–4]. Examination of the genetic polymorphisms may help
to interpret the variation in individual lung cancer risk.
The p53 tumor suppressor gene, being located on chromo-
some 17p13, is one of the most frequently mutated genes in
human cancer with a predominance of missense mutations
scattered over 200 codons [5]. The encoded p53 protein can be
activated by a variety of cellular stresses, which plays pivotal
roles in the maintenance of genomic stability, the regulation of
apoptosis, and cell cycle by transactivating the downstream
target genes [6]. Mutations of the p53 gene may result in loss
of its tumor suppressor function and thus contribute to the
carcinogenesis and/or tumor progression. The polymorphism
of p53 codon 72, a transversion of G to C (Arg to Pro), has
been shown to be related to the risk of some malignant tumors
[7–9]. It has been confirmed that the two polymorphic var-
iants, Arg and Pro, of p53 codon 72 differ biochemically and
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biologically [10, 11]. Therefore, the polymorphism of p53
codon 72 Arg/Pro may exert different effects on diverse
types of cancer or even the same cancer in different
populations. The homozygote genotype Arg/Arg was
found to be significantly associated with an increased
risk of cervical cancer in a previous meta-analysis [12].
Nevertheless, a recent meta-analysis by Liu et al. sug-
gested that the p53 codon 72 Arg/Arg genotype played
a protective role in gastric cancer risk among Asians
[13]. Regarding the lung cancer risk, the effect of p53
codon 72 Arg/Pro polymorphism on the Asian patients
remained unclear due to the conflicting and inconclusive
findings across individual studies. The aim of this meta-
analysis with a large amount of available data was to
estimate the association of p53 codon 72 Arg/Pro poly-
morphism with lung cancer risk in the Asian population.
Materials and methods
Search strategy and identification of relevant studies
We performed a comprehensive search of the PubMed,
Embase, Web of Science, and Wanfang databases to
identify potentially relevant studies on the association
between p53 codon 72 Arg/Pro polymorphism and lung
cancer risk up to December 6, 2012. All eligible studies
were retrieved. Reviews and the references of eligible
studies were hand-searched for additional relevant pub-
lications. When more than one publications with over-
lapping data, the most recent or complete one was
selected. The following terms were used in the literature
search: p53, p53 codon 72, p53 codon 72 Arg/Pro, or
rs1042522; and lung cancer, lung carcinoma, or lung;
and polymorphism, polymorphisms, or mutation.
Inclusion criteria
Studies were included into the meta-analysis if they satisfied
the following criteria: (1) assessing the association of p53
codon 72 Arg/Pro polymorphism with lung cancer risk; (2)
applying a case–control design; (3) and providing the fre-
quencies of both alleles and genotypes in cases and controls
or available information to calculate them. Case-only stud-
ies and reviews were all excluded.
Data extraction
Data were carefully extracted independently by two investi-
gators from all included studies according to the above inclu-
sion criteria. Disagreements were resolved by discussion. The
extracted data comprised the following items: surname of the
first author, publication year, country of origin, summary
characteristics of cases and controls, genotyping method,
number of cases and controls, frequencies of the alleles and
genotypes in cases and controls, matching factor, smoking
status of subjects, source of controls, and the Hardy–Weinberg
equilibrium (HWE) of genotype distribution among controls.
Subjects were divided into smokers and nonsmokers based on
their smoking history. According to the histological types of
lung cancer, two subgroups of squamous cancer (SC) and
adenocarcinoma (AC) were made. In addition, subgroups of
hospital-based study and population-based study were
assigned by the source of controls.
Statistical analysis
The pooled odds ratios (ORs) with the corresponding 95 %
confidence intervals (95 %CIs) were used to evaluate the
strength of the association between p53 codon 72 Arg/Pro
polymorphism and lung cancer risk. Five genetic contrast
models involving the allelic (Pro allele vs. Arg allele), homo-
zygous (Pro/Pro vs. Arg/Arg), additive (Arg/Pro vs. Arg/Arg),
recessive (Pro/Pro vs. Arg/Arg + Arg/Pro), and dominant
(Arg/Pro + Pro/Pro vs. Arg/Arg) models were applied. The
chi-square-based Q statistic test and I2 test were adopted to
estimate the between-study heterogeneity among all included
studies, and the heterogeneity was statistically significant if
the p value is less than 0.05 and the I2 is more than 50 % [14,
15]. The fixed-effect model by the Mantel–Haenszel's method
was used to calculate the pooled ORs when the between-study
heterogeneity was significant [16]; otherwise, the random-
effect model by DerSimonian and Laird's method was applied
[17]. The pooled ORs were estimated by use of Z statistic test
with the significance level set at p<0.05. Subgroup analyses
by source of controls, histological types of lung cancer, and
smoking status were performed to further identify the associ-
ation between p53 codon 72 Arg/Pro polymorphism and lung
cancer susceptibility. Sensitivity analysis by sequential omis-
sion of any individual studies was also conducted to confirm
the stability and reliability of the pooled results in the meta-
analysis [18]. Both Begg's funnel plot and Egger's test were
adopted to evaluate the publication bias in our meta-analysis
[19, 20]. All statistical analyses were performed by STATA
12.0 software (StataCorp, College Station, TX, USA).
Results
Study characteristics
A total of 14 case–control studies on the association of p53
codon 72 Arg/Pro polymorphism and lung cancer risk in Asian
population were retrieved based on the inclusion criteria
[21–34]. The characteristics of all studies were summarized in
Table 1. The included studies were mainly carried out in China,
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Japan, Korea, Singapore, and USA. Among the 14 publica-
tions, ten ones were published in English [21–30] and the others
were in Chinese [31–34]. According to the source of controls,
nine individual studies including 6,228 cases and 4,420 controls
were categorized into population-based case–control studies,
four involving 699 cases and 819 controls were hospital-based
case–control studies, and still one with 1,687 subjects was
conducted in a mixed population. The genotype distribution
in controls of the included studies all agreed with HWE, except
the two ones by Liu et al. and Shao et al., respectively. The
genotype frequencies for Arg/Arg, Pro/Pro, and Arg/Pro of
cases and controls were presented in Table 1 in detail.
Meta-analysis results
Total studies
The pooled ORs of all included case–control studies revealed
that there was a statistically significant association between the
p53 codon 72 Arg/Pro polymorphism and lung cancer risk in
the dominant model (ORArg/Pro + Pro/Pro vs. Arg/Arg=1.14, 95%CI
1.07–1.23, POR<0.001), while no significant association was
found in other genetic models (ORPro allele vs. Arg allele=1.11,
95 %CI 1.00–0.24, POR=0.062; ORPro/Pro vs. Arg/Arg=1.23,
95 %CI 0.98–1.54, POR=0.077; ORArg/Pro vs. Arg/Arg=1.07,
95 %CI 0.99–1.16, POR=0.072; ORPro/Pro vs. Arg/Arg + Arg/Pro=
1.22, 95 %CI 0.98–1.53, POR=0.073) (Table 2 and Fig. 1).
However, individuals carrying the mutant Pro allele were more
likely to develop lung cancer, although there is lack of statisti-
cal significance in the allelic, homozygous, additive, and reces-
sive genetic models.
Subgroup analysis by source of controls
In stratifying analysis by source of controls, significantly
increased risk was found when comparing the combined
genotype Arg/Pro + Pro/Pro with Arg/Arg in population-
based studies (ORArg/Pro + Pro/Pro vs. Arg/Arg=1.17, 95 %CI
1.07–1.27, POR<0.001). Similarly, a positive association
was found in the allelic, homozygous, additive, and recessive
models, but there was no statistical significance (Table 2).
Interestingly, the variant of p53 codon 72 Arg/Pro was nega-
tively associated with lung cancer risk in the subgroup anal-
ysis of hospital-based studies (Table 2). Nevertheless, the
finding may be a chance, in that there were only four individ-
ual hospital-based studies with a total of 699 cases and 819
controls included into our meta-analysis.
Subgroup analysis by histological types of lung cancer
Among individuals with SC and AC of lung cancer, no
statistically significant association of the p53 codon 72
Arg/Pro polymorphism with lung cancer risk was observed
Table 1 Summary characteristic for all included studies in the meta-analysis
First author Year Source of controls Country HWE Genotype distribution in cases and controls Matching factor
Pro/Pro Arg/Pro Arg/Arg Pro/Pro Arg/Pro Arg/Arg
Murata M 1996 HCC Japan + 22 89 80 37 131 99 Age and gender
Wang YC 1999 HCC China + 52 74 68 30 75 47 Age
Pierce LM 2000 PCC USA + 19 51 41 23 65 82 Sex, ethnicity, and age
Hiraki A 2003 HCC Japan + 24 99 68 43 106 90 Age and gender
Zhang JH 2003 PCC China + 32 45 21 27 69 40 Age, gender, ethnicity,
and residence
Shao GG 2005 PCC China NR 48 16 24 37 42 33 Ethnicity and residence
Sakiyama T 2005 Mixed Japan + 144 460 398 73 310 302 Age, race, and smoking
history
Zhang X 2006 PCC China + 279 506 321 264 731 425 Age, gender, ethnicity,
and residence
Jung HY 2008 PCC Korea + 42 130 108 37 136 120 NR
Li RN 2009 PCC China + 17 58 50 22 42 37 Ethnicity and residence
Chua HW 2010 HCC Singapore + 26 69 28 31 88 42 The hospital, age, and
frequency
Wang W 2010 PCC China + 35 45 44 20 58 50 Ethnicity and residence
Piao JM 2011 PCC Korea + 657 1,821 1,458 190 776 734 Age and gender
Liu D 2012 PCC China NR 79 137 144 119 115 126 Age, gender, ethnicity,
frequency, and residence
HCC hospital-based case–control study, PCC population-based case–control study, HWE Hardy–Weinberg equilibrium, NR not reported
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under all genetic contrast models (Table 2). Additionally,
patients with SC had lower frequencies of Pro/Pro genotype
and Pro allele in comparison with the AC patients, although
there was no statistical significance (Table 2).
Table 2 Meta-analysis results
for the p53 codon 72 polymor-
phism and lung cancer risk
OR odds ratio, 95 %CI 95 %
confidence interval, PH P value
of heterogeneity analysis, SC
squamous cancer, AC
adenocarcinoma
Group/subgroup Cases/controls Odds ratio I2 (%) PH
OR [95 %CI] POR
Total studies 7,929/5,924
Pro allele vs. Arg allele 1.11 [1.00–1.24] 0.062 70.6 <0.001
Pro/Pro vs. Arg/Arg 1.23 [0.98–1.54] 0.077 70.9 <0.001
Arg/Pro vs. Arg/Arg 1.07 [0.99–1.16] 0.072 21.9 0.216
Arg/Pro + Pro/Pro vs. Arg/Arg 1.14 [1.07–1.23] <0.001 32.6 0.115
Pro/Pro vs. Arg/Arg + Arg/Pro 1.22 [0.98–1.53] 0.073 76.2 <0.001
Hospital-based studies 699/819
Pro allele vs. Arg allele 0.97 [0.84–1.12] 0.687 0.0 0.606
Pro/Pro vs. Arg/Arg 0.93 [0.69–1.27] 0.655 0.0 0.460
Pro/Arg vs. Arg/Arg 0.95 [0.76–1.19] 0.666 28.1 0.244
Pro/Arg + Pro/Pro vs. Arg/Arg 0.95 [0.77–1.18] 0.631 0.0 0.550
Pro/Pro vs. Arg/Arg + Pro/Arg 0.98 [0.75–1.28] 0.887 44.2 0.146
Population-based studies 6,228/4,420
Pro allele vs. Arg allele 1.16 [0.99–1.35] 0.059 77.7 <0.001
Pro/Pro vs. Arg/Arg 1.32 [0.97–1.78] 0.073 77.6 <0.001
Arg/Pro vs. Arg/Arg 1.08 [0.99–1.18] 0.077 28.2 0.193
Arg/Pro + Pro/Pro vs. Arg/Arg 1.17 [1.07–1.27] <0.001 42.1 0.087
Pro/Pro vs. Arg/Arg + Arg/Pro 1.32 [0.98–1.77] 0.069 81.8 <0.001
Histological types
SC 1,062/3,199
Pro allele vs. Arg allele 0.99 [0.65–1.50] 0.951 92.0 <0.001
Pro/Pro vs. Arg/Arg 0.96 [0.40–2.28] 0.919 91.6 <0.001
Arg/Pro vs. Arg/Arg 1.04 [0.88–1.23] 0.648 44.4 0.145
Arg/Pro + Pro/Pro vs. Arg/Arg 1.06 [0.75–1.49] 0.762 74.1 0.009
Pro/Pro vs. Arg/Arg + Arg/Pro 0.94 [0.52–1.69] 0.827 86.8 <0.001
AC 1,602/3,199
Pro allele vs. Arg allele 1.01 [0.84–1.21] 0.935 65.7 0.033
Pro/Pro vs. Arg/Arg 1.17 [0.96–1.44] 0.125 59.7 0.059
Arg/Pro vs. Arg/Arg 1.02 [0.88–1.19] 0.805 11.3 0.336
Arg/Pro + Pro/Pro vs. Arg/Arg 1.05 [0.91–1.21] 0.491 49.2 0.116
Pro/Pro vs. Arg/Arg + Arg/Pro 1.03 [0.73–1.47] 0.853 71.2 0.002
Smoking status
Smokers 2,139/1,868
Pro allele vs. Arg allele 0.92 [0.66–1.27] 0.595 85.5 <0.001
Pro/Pro vs. Arg/Arg 0.86 [0.45–1.65] 0.642 85.7 <0.001
Arg/Pro vs. Arg/Arg 0.95 [0.79–1.13] 0.561 0.0 0.552
Arg/Pro + Pro/Pro vs. Arg/Arg 1.06 [0.91–1.25] 0.528 28.6 0.240
Pro/Pro vs. Arg/Arg + Arg/Pro 1.08 [0.68–1.71] 0.744 82.7 <0.001
Nonsmokers 1,247/2,139
Pro allele vs. Arg allele 1.04 [0.92–1.18] 0.521 48.3 0.102
Pro/Pro vs. Arg/Arg 1.15 [0.90–1.46] 0.272 0.0 0.521
Arg/Pro vs. Arg/Arg 0.77 [0.52–1.15] 0.207 64.7 0.023
Arg/Pro + Pro/Pro vs. Arg/Arg 0.86 [0.61–1.20] 0.371 59.3 0.043
Pro/Pro vs. Arg/Arg + Arg/Pro 1.24 [0.89–1.74] 0.195 42.6 0.083
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NOTE: Weights are from random effects analysis
Overall  (I-squared = 70.6%, p = 0.000)
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Fig. 1 Forest plots for the association of P53 codon 72 polymorphism
and lung cancer risk in total studies. a Pro allele vs. Arg allele, the
allelic model. b Pro/Pro vs. Arg/Arg, the homozygous model. c Arg/
Pro vs. Arg/Arg, the additive model. d Pro/Pro vs. Arg/Arg + Arg/Pro,
the recessive model. e Arg/Pro + Pro/Pro vs. Arg/Arg, the dominant
model
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Fig. 1 (continued)



















































NOTE: Weights are from random effects analysis
Overall  (I-squared = 76.2%, p = 0.000)
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Subgroup analysis by smoking status
When stratifying by smoking status, the p53 codon 72
Arg/Pro variant was not related to increased or decreased
risk of lung cancer in mutant Pro carriers no matter smoking
or not (Table 2). Besides, the nonsmokers had higher fre-
quencies of Pro/Pro genotype and Pro allele compared with
the smokers, but lack statistical significance (Table 2).
Heterogeneity and sensitivity analyses
The between-study heterogeneity was significant in allelic, ho-
mozygous, and recessive models among total studies (Pro allele
vs. Arg allele, I2=70.6,PH<0.001; Pro/Pro vs. Arg/Arg, I
2=70.9,
PH<0.001; Pro/Pro vs. Arg/Arg + Arg/Pro, I
2=76.2, PH<0.001)
(Table 2); consequently, the random-effect model was used to
estimate the pooled ORs. In reverse, the pooled ORs for Arg/Pro
vs. Arg/Arg and Arg/Pro + Pro/Pro vs. Arg/Arg were evaluated
by fixed-effect model (Table 2). We made subgroup analysis to
identify the between-study heterogeneity among the included
studies. No significant heterogeneity was observed among the
hospital-based studies, but the population-based ones (Table 2).
Sensitivity analysis by sequential omission of individual studies
one at a time confirmed the stability and reliability of the results in
our meta-analysis (data not shown).
Publication bias
The publication bias was evaluated by Begg's funnel plot and
Egger's test. No visual asymmetry was found in the funnel plot
analysis (Fig. 2), suggesting no publication bias among the
included studies. In addition, the results of Egger's tests for all
genetic models also did not indicate publication bias in the
present meta-analysis (data not shown).
Discussion
The p53 codon 72 Arg/Pro variant, the most informative
polymorphism of p53 gene, has been found to be significantly
associated with an increased risk of lung cancer in a previous
meta-analysis [35]. However, not all publications included
into the meta-analysis agreed with HWE, and only eight
individual studies were conducted in the Asian population.
Moreover, they did not assess the role of p53 codon 72
Arg/Pro polymorphism in lung cancer risk concerning the
histological types of lung cancer and smoking status among
Asians. In the present meta-analysis, a significant relationship
of the p53 codon 72 Arg/Pro variant with lung cancer risk was
identified under the dominant genetic model in overall
(ORArg/Pro + Pro/Pro vs. Arg/Arg=1.14) and the subgroup analyses
Fig. 1 (continued)
Overall  (I-squared = 32.6%, p = 0.115)
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of population-based studies (ORArg/Pro + Pro/Pro vs. Arg/Arg=
1.17) in Asians. A slightly but not statistically significant
association was found in the allelic, homozygous, additive,
and recessive contrast models. Additionally, no statistically
significant correlation was observed under all genetic contrast
models in subgroup analyses according to the histological
types of lung cancer and smoking status.
Lung cancer risk increases with cigarette smoking and
other environmental exposures. Zhou et al. found that smok-
ing could modify the effects of X-ray cross-complementing
group 1 and excision repair cross-complementing group 2
polymorphisms on the risk for lung cancer, indicating a
gene–environmental interaction in the lung carcinogenesis
[36]. It has been well-established that there is a range of
genetic susceptibility to lung cancer risk, such as microsomal
epoxide hydrolase 1, matrix metalloproteinase-1, and gluta-
thione S-transferase P1 [37–39]. In addition, the polymor-
phism of p53 codon 72 Arg/Pro also has been demonstrated
to modify the risk for lung cancer among Asians in many
previous case–control studies [21–34]. Murata et al. initially
reported that the Arg/Arg homozygote seemed to be suscep-
tible to smoking-unrelated lung cancer, while the Pro/Pro
homozygote did not exert effects on the risk of this deadly
disease [21]. A recent study by Liu et al. revealed that the
frequencies of Pro/Pro genotype and Pro allele were lower in
lung cancer patients and might modify the risk for smoking-
related lung cancer in a Chinese population [30]. Reversely,
our meta-analysis of all included studies showed that the
Pro/Pro genotype and Pro allele were predominant in Asians
with lung cancer, although there is lack of statistical signifi-
cance. Interestingly, the mutant Pro/Pro genotype and Pro
allele of p53 codon 72 played a protective but not statistically
significant role in lung cancer risk in subgroup analysis of
hospital-based studies. Nevertheless, there were only four
individual hospital-based studies involving 699 cases and
819 controls included in this meta-analysis. Studies with small
sample size were insufficient enough in statistical power to
determine a true association. When stratifying by the histolog-
ical types of lung cancer, patients with SC had lower frequen-
cies of Pro/Pro genotype and Pro allele compared with patients
with AC, although there was no statistical significance. When
considering the stratified analysis based on the smoking sta-
tus, the frequencies of Pro/Pro genotype and Pro allele were
lower but not statistically significant in smoking-related lung
cancer patients, similar to the finding by Liu et al. [30].
The frequencies of p53 codon 72 alleles and haplotypes
differ across ethnicities [40], which may be the leading cause
for different effects of the p53 codon 72 Arg/Pro polymor-
phism on lung cancer risk in different ethnicities. Significantly
increased risks for lung cancer were found among Asians, but
not Africans for both the homozygote Pro/Pro and the Pro
allele carriers in a previous meta-analysis by Li et al. [41].
Similarly, the present meta-analysis with more available data
suggests that the p53 codon 72 Arg/Pro variant is a risk factor
for lung cancer in Asians. The inconsistent findings among
ethnicities may be attributed to different genetic backgrounds
and environments. Furthermore, the effect of p53 codon 72
Arg/Pro polymorphism on lung cancer risk differs in Asians.
Jung et al. demonstrated that the p53 codon 72 Arg/Pro
polymorphism was not significantly associated with lung
cancer susceptibility in a Korean population [27]. On the
contrary, the p53 codon 72 polymorphism was confirmed to
be related to an elevated risk of lung cancer in another Korean
population [29]. Different study design, sample size, genotyp-
ing method, and source of controls may be responsible for the
conflicting findings among individual studies.
To the best of our knowledge, tobacco smoking is a major
risk factor for lung cancer. It can affect carcinogenesis by
interacting with the genetic polymorphisms. Tobacco carcino-
gens have been shown to exert a direct mutagenic action on
DNA, particularly on p53 [42]. The study by Liu et al. sug-










Fig. 2 Begg's funnel plot with
pseudo-95 % confidence limits
for estimating the publication
bias
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smoking-related lung cancer risk, indicating the smoking–
gene interplay in lung carcinogenesis [30]. Nevertheless, we
found that the p53 codon 72 Arg/Pro polymorphism was not
significantly associated with the risk of lung cancer no matter
among smokers or nonsmokers. Future studies with high
quality and large sample size may further explore the potential
role of gene–environment interactions in lung cancer risk.
Some limitations should be acknowledged when eluci-
dating the results of our meta-analysis. Firstly, the genotype
distribution of p53 codon 72 among controls was not all in
agreement with HWE among total included studies. Second-
ly, as above mentioned, the appreciable association of smok-
ing–gene interplay with lung cancer risk needs further
confirmation in more future studies with high quality. Last
but not the least, the p53 codon 72 Arg/Pro polymorphism
may modify the risk for lung cancer among Asians in
combination with other genetic polymorphisms, such as
cytochrome P-450 1A1 [43] and p21 Ser31Arg [44]. Thus,
the possible effect of gene–gene interactions on lung cancer
risk is recommended to be further investigated.
In summary, our meta-analysis shows a significant associ-
ation between the p53 codon 72 Arg/Pro polymorphism and
lung cancer risk in the Asian population. However, we failed
to identify this association regarding the smoking status and
histological types of lung cancer patients. In addition, the
potential effect of gene–gene and gene–environment interac-
tions on lung cancer development needs further investigation
in future studies.
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